AstraZeneca ends collaboration with Targacept

It seems that drug development challenges have forced the companies to end their research collaboration


(Photo Courtesy:

AstraZeneca terminated its collaborative research and license agreement with Targacept, a North Carolina-based, US biopharmaceutical company.

The collaboration started in 2005, and is now terminated after nearly 9 years.

The termination becomes effective 90 days after October 8, 2014.

The decision will end the collaboration on TC-6683 compound.

All the rights and licenses on this compound will be returned to Targacept.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email